The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. —All six […]
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS companyPositive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease […]